News | October 11, 2013

Promising Durability Data Presented for BioVentrix’s Heart Failure Treatment

Less-invasive procedure extends options for heart failure patients

heart failure treatments clinical trial/study bioventrix revivent LIVE

October 11, 2013 — Bioventrix announced the presentation of scientific data demonstrating the durability of its Revivent Myocardial Anchoring System in 24 patients one year post-procedure. The data, which Andrew Wechsler, M.D. and professor of cardiothoracic surgery, Drexel University, presented at the prestigious European Association for Cardio-Thoracic Surgery meeting in Vienna, Austria, highlighted results from the company’s Phase I clinical trial conducted at five European centers.

Twenty-four patients suffering from class II-IV heart failure (HF) — as defined by the New York Heart Association (NYHA) functional class criteria — as a result of a previous heart attack have now passed the one-year milestone since their HF was treated using the Revivent System via Less Invasive Ventricular Enhancement (LIVE) procedure. In the data presented, 24 of 26 patients sustained a reduction in left ventricle volume to a mean of 43.9 + 22 mL/m2 — a mean 40 percent decrease.[1] Additionally, quality-of-life scores increased 30.9 percent.

“When a significant percentage of patients are doing well at this juncture, it suggests that the technology will be durable and lasting in the general heart failure population,” said Andrew Wechsler, M.D. “The results achieved with the Revivent System and the LIVE procedure are extremely encouraging, especially for the millions of patients suffering from heart failure worldwide who have become so frail due to their heart disease that they are no longer candidates for more invasive, conventional surgery.”

The Revivent Myocardial Anchoring System is approved for sale in Europe; it is not approved for sale in the United States. The Revivent-TC Myocardial Anchoring System is not yet approved for sale in Europe or in the United States.

For more information: www.bioventrix.com

References:
[1] Wechsler, A. et al, Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Abstract xx, XX annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna Austria

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init